open access
New developments in the perioperative treatment of melanomas with locoregional advancement
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland
- Faculty of Medicine and Health Studies, A. Frycz-Modrzewski Krakow Academy, Poland
- Scientific Office, Maria Skłodowska-Curie Institute – Oncology Center, Warsaw, Poland
- General, Oncological and Vascular Surgery Clinic, 5 Military Clinical Hospital in Krakow, Poland
- Oncological Surgery Clinic, Medical University in Łódź, Poland
open access
Abstract
Surgical intervention is the treatment of choice for patients with melanomas. However, the prognoses of the patients with melanomas at the IIC–IV stage, even after a complete resection of the lesions, is very diverse and, to a great degree, connected with a high risk of disease recurrence. The positive results of the studies in this area have resulted in systemic adjuvant therapy becoming the standard for patients in this group. New methods of systemic treatment – both the molecularly targeted treatment with BRAF and MEK inhibitors (dabrafenib with trametinib) and anti-PD-1 immunotherapy (nivolumab or pembrolizumab) – are already registered in the United States and the European Union. Also the results of the studies concerning the use of preoperative systemic treatment in patients with loco-regionally advanced melanomas seem to be very promising.
Abstract
Surgical intervention is the treatment of choice for patients with melanomas. However, the prognoses of the patients with melanomas at the IIC–IV stage, even after a complete resection of the lesions, is very diverse and, to a great degree, connected with a high risk of disease recurrence. The positive results of the studies in this area have resulted in systemic adjuvant therapy becoming the standard for patients in this group. New methods of systemic treatment – both the molecularly targeted treatment with BRAF and MEK inhibitors (dabrafenib with trametinib) and anti-PD-1 immunotherapy (nivolumab or pembrolizumab) – are already registered in the United States and the European Union. Also the results of the studies concerning the use of preoperative systemic treatment in patients with loco-regionally advanced melanomas seem to be very promising.
Keywords
melanoma; adjuvant treatment; preoperative treatment; BRAF inhibitors; MEK inhibitors; immunotherapy; anti-PD-1
Title
New developments in the perioperative treatment of melanomas with locoregional advancement
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Review paper
Pages
97-102
Published online
2019-10-31
Page views
477
Article views/downloads
564
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2019;69(3-4):97-102.
Keywords
melanoma
adjuvant treatment
preoperative treatment
BRAF inhibitors
MEK inhibitors
immunotherapy
anti-PD-1
Authors
Piotr Rutkowski
Wojciech M. Wysocki
Tomasz Świtaj
Arkadiusz Jeziorski